KLOW Blend (BPC-157 / TB-4 / GHK-Cu / KPV)

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

KLOW Blend — Quadruple-Peptide Research Formulation (BPC-157 / TB-4 / GHK-Cu / KPV)

KLOW is a research blend combining four structurally and mechanistically distinct peptides into a single lyophilized formulation: Body Protection Compound-157 (BPC-157), thymosin beta-4 fragment (TB-4), copper-binding tripeptide GHK-Cu, and KPV (Lys-Pro-Val). Each component has a distinct primary mechanism — BPC-157 operates via nitric oxide and growth factor receptor pathways; TB-4 through actin sequestration and thymosin beta-4’s N-terminal fragment activity; GHK-Cu through copper-dependent transcriptional regulation of wound-healing and antioxidant genes; and KPV as a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) with NF-κB-mediated anti-inflammatory signaling. The rationale for combining these four compounds in research is that they address complementary stages of the tissue response cascade — initial inflammation modulation (KPV), nitric oxide-dependent vascular and cellular repair signaling (BPC-157), extracellular matrix remodeling and actin cytoskeleton dynamics (TB-4), and copper-mediated transcriptional amplification of repair gene networks (GHK-Cu). KLOW 80mg represents a fixed-ratio formulation of all four components as a single vial for structured research protocols.

Why the Four-Component Combination Addresses Different Phases of the Research Cascade

KPV’s anti-inflammatory action via MC1R and NF-κB suppression is rapid and upstream; it reduces pro-inflammatory cytokine output at the initiation phase. BPC-157 stabilizes nitric oxide production and modulates growth factor receptor signaling across multiple tissue types, acting as a broad cellular repair signaling compound. TB-4 — or more precisely its active fragment Ac-SDKP — promotes actin polymerization dynamics and endothelial migration relevant to vascular repair models. GHK-Cu then provides copper-dependent transcriptional input to genes encoding collagen, fibronectin, and superoxide dismutase, amplifying the reparative phase at the ECM and antioxidant level. Used in combination, these mechanisms do not overlap substantially, which is the mechanistic basis for studying them as a unified compound in multi-endpoint research frameworks.

Research Applications

KLOW Blend is used in studies examining:

• Multi-pathway tissue repair and regeneration model design
• NF-κB-driven inflammatory cascade modulation (KPV component)
• Nitric oxide-dependent cellular signaling and vascular repair (BPC-157 component)
• Extracellular matrix gene regulation via copper-peptide complexes (GHK-Cu component)
• Actin dynamics and cellular migration in wound and angiogenesis models (TB-4 component)
• Combined anti-inflammatory and pro-repair endpoint studies requiring simultaneous multi-pathway interrogation

Specifications

Reconstitution

KLOW Blend arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total mg ÷ Volume added (mL) = Concentration (mg/mL)

Example: 80mg vial + 8mL BAC water = 10mg/mL total blend solution

Reconstituted blend should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

As a blend product, KLOW research frameworks are derived from the published literature for each individual component. Researchers designing protocols using KLOW should account for the dose contribution of each component per volume drawn. The dose ranges below reflect ranges observed in rodent in vivo literature for each compound used individually.

• BPC-157 literature range: 1–10 mcg/kg SC or IP in rodent models; 250–500ng/kg in some GI studies
• TB-4 literature range: 1–6mg/kg in rodent wound and cardiac models
• GHK-Cu literature range: 1–50 mg/kg in skin and wound healing rodent studies
• KPV literature range: 50–200 mcg/kg in rodent inflammatory bowel and systemic inflammation models
• Study duration: 1–4 weeks typical in rodent tissue repair models

Research Stacks

KLOW Blend is commonly paired in research settings with:

• BPC-157 — BPC-157 promotes angiogenesis and connective tissue repair via NO-pathway and growth factor modulation; pairing with KLOW’s KPV and TB-4 components is studied for potentially overlapping and complementary activity across mucosal healing, tendon repair, and inflammatory resolution models.
• GHK-Cu — GHK-Cu is a copper-binding tripeptide with documented ECM remodeling and anti-inflammatory activity; researchers pair it with KLOW to examine whether additional exogenous GHK-Cu amplifies the copper-peptide component already present in the blend.
• Thymosin Alpha-1 — Thymosin Alpha-1 modulates innate and adaptive immune signaling via TLR-pathway activation; combining it with KLOW’s immune-modulating KPV fraction is studied to assess coordinated anti-inflammatory and immune-regulatory activity across tissue and systemic compartments.

Purity Guarantee

Every batch is ≥99% purity per component. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.